Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders  Mai F. Tolba, Hany A.

Slides:



Advertisements
Similar presentations
Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.
Advertisements

Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein Stefano Angiari, Gabriela Constantin Trends in Molecular.
Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature María Teresa Martínez, José Alejandro Pérez-Fidalgo, Paloma Martín-Martorell,
Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /
Eribulin—A review of preclinical and clinical studies
Gastric cancer Critical Reviews in Oncology / Hematology
Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi 
Lipid metabolism and lung cancer
Exercise issues in older cancer survivors
Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review  Cloé Brami, Ting Bao, Gary Deng  Critical.
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma  André Veillette, Huaijian Guo  Critical Reviews.
Novel targets in gastric and esophageal cancer
Critical Reviews in Oncology / Hematology
Volume 96, Pages 5-8 (November 2016)
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.
Nicoletta Colombo, Martin Gore 
A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications  Mitchell E. Reff, Cheryl Heard  Critical Reviews.
Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions?  Séverine Guiu, Anita Wolfer, William Jacot, Pierre.
Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force  Silvio Monfardini,
Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis 
The case for wider use of recombinant factor VIII concentrates
P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency 
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature  Omar Abdel-Rahman,
Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey  Lazzaro Repetto  Critical.
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.
The see-saw of Keap1-Nrf2 pathway in cancer
Amy M. Lin, Charles J. Ryan, Eric J. Small 
Mast cells in breast cancer angiogenesis
Genistein: Its role in metabolic diseases and cancer
Jonathan P. Evans, Paul A. Sutton, Boleslaw K. Winiarski, Stephen W
Volume 64, Pages e1-e3 (January 2017)
Abhimanyu Ghose, Ria Kundu, Tahir Latif 
Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment  Judith Maresch, Sebastian F. Schoppmann,
P. Therasse, S. Carbonnelle, J. Bogaerts 
Olfa Baroudi, Amel Benammar-elgaaied 
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?  Pieter Sonneveld,
Long non-coding RNA CASC2 in human cancer
Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward 
Critical Reviews in Oncology / Hematology
Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence  Ashish Singhal, Muralidharan Jayaraman, Danny.
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario  Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello  Critical.
Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis of.
Gerhard J. Molderings  Critical Reviews in Oncology / Hematology 
Volume 71, Issue 2, Pages (February 2017)
Figure 3 Altered adaptive immune functions after sepsis
Figure 1 Four nodes to target when inducing anti-tumour immunity
Oncology Meets Immunology: The Cancer-Immunity Cycle
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.
Georges Makhoul, MD, MS, Ray C.J. Chiu, MD, PhD, Renzo Cecere, MD, MS 
Unraveling the Pros and Cons of Interferon-γ Gene Regulation
Leonardo V. Riella, Mohamed H. Sayegh  Kidney International Supplements 
EGFR signaling in renal fibrosis
Targets for immunotherapy of liver cancer
Immunotherapy of aspergillosis
The yin and yang of evasion and immune activation in HCC
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Volume 137, Issue 1, Pages (July 2009)
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Volume 33, Issue 4, Pages (October 2010)
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Erratum Journal of Thoracic Oncology
Nat. Rev. Urol. doi: /nrurol
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
CAMTA in Cardiac Hypertrophy
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Releasing the Brakes on Cancer Immunotherapy
Cytokine Gene Therapy for Malignant Pleural Mesothelioma
Volume 12, Issue 6, Pages (December 2007)
Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy  Robert D. Leone, Maureen R. Horton, Jonathan D.
Presentation transcript:

Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders  Mai F. Tolba, Hany A. Omar  Critical Reviews in Oncology / Hematology  Volume 122, Pages 202-207 (February 2018) DOI: 10.1016/j.critrevonc.2018.01.005 Copyright © 2018 Elsevier B.V. Terms and Conditions

Fig. 1 Diagram depicting the implemented immunotherapeutic strategies to convert non-responders triple negative breast cancer to responders. STING, stimulator of interferon genes; TGF-β, transforming growth factor beta; PEGPH20, PEGylated recombinant hyaluronidase; HDAC, Histone deacetylases; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; CTLA-4, cytotoxic T lymphocyte associated protein-4; IDO-indoleamine dehydrogenase. Critical Reviews in Oncology / Hematology 2018 122, 202-207DOI: (10.1016/j.critrevonc.2018.01.005) Copyright © 2018 Elsevier B.V. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.